lurbinectedin SCLC
Selected indexed studies
- Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial. (Lancet, 2025) [PMID:40473449]
- Small Cell Lung Cancer: A Review. (JAMA, 2025) [PMID:40163214]
- Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial. (Lancet Oncol, 2020) [PMID:32224306]
_Worker-drafted node — pending editorial review._
Connections
lurbinectedin SCLC is a side effect of
Sources
- Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial. (2025) pubmed
- Small Cell Lung Cancer: A Review. (2025) pubmed
- Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial. (2020) pubmed
- Lurbinectedin sensitizes PD-L1 blockade therapy by activating STING-IFN signaling in small-cell lung cancer. (2024) pubmed
- Lurbinectedin Plus Pembrolizumab in Relapsed SCLC: The Phase I/II LUPER Study. (2025) pubmed
- Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial. (2023) pubmed
- Lurbinectedin for extensive stage - small cell lung cancer (ES-SCLC): real world response patterns and survival outcomes. (2025) pubmed
- Lurbinectedin: First Approval. (2020) pubmed
- Adding lurbinectedin to maintenance therapy improves outcomes in ES-SCLC. (2025) pubmed
- Top advances of the year: Small cell lung cancer. (2025) pubmed